finance.yahoo.com
Positivefinance.yahoo.com ·
Baird Maintains Bullish View Boston
InvestorArmedconflictNational SecurityHealth
Topic context
This topic has been covered 418979 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe news covers analyst rating changes and a share buyback for Boston Scientific, a medical device company. The TAVR re-entry via MiRus is a modest revenue opportunity. No direct commodity or supply chain impact; the commercial mechanism is limited to equity valuation and capital allocation. Impact is company-specific.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Baird lowered BSX price target from $78 to $75 but maintains bullish outlook.
- Boston Scientific re-entered TAVR market via stake in MiRus.
- BofA reduced BSX price target from $105 to $68, citing medtech valuation shift.
- Boston Scientific announced $2 billion accelerated share repurchase with JPMorgan.
- Buyback program totals $5 billion, expected completion by June 30, 2026.
